{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004270","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.970507+00:00","generated_at":"2026-05-31T14:40:47.309579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance","bullets":["Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.","Generics grew 16% US, 8% Europe, 22% International; AUSTEDO US revenue $407M (+32%).","Raised 2024 guidance: revenue $16.0-16.4B, non-GAAP EPS $2.30-2.50, adj. EBITDA $4.6-5.0B.","Pipeline: duvakitug top-line now Q4 2024; olanzapine LAI positive Phase 3; SIMLANDI launch.","Free cash flow $324M; $506M tax hit from Israeli Tax Authority settlement."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004270","json":"https://secwatch.observer/filing/0001171843-24-004270.json","markdown":"https://secwatch.observer/filing/0001171843-24-004270.md","text":"https://secwatch.observer/filing/0001171843-24-004270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184324004270/0001171843-24-004270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184324004270/f8k_073124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:40:47.309579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}